Trump's de minimis delay leaves DTC brands in turmoil, struggling to plan amid sudden policy changes.
In a report released today, Stephen Willey from Stifel Nicolaus maintained a Hold rating on Bolt Biotherapeutics (BOLT – Research Report), with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback